Prevention of Transition From Incipient to Overt Nephropathy With Telmisartan in Patients With Type 2 Diabetes (original) (raw)

Skip Nav Destination

Clinical Care / Education / Nutrition| June 01 2007

Hirofumi Makino, MD;

1Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan

Search for other works by this author on:

Masakazu Haneda, MD;

2Department of Medicine, Division of Metabolism and Biosystemic Science, Asahikawa Medical College, Hokkaido, Japan

Search for other works by this author on:

Tetsuya Babazono, MD;

3Division of Nephrology and Hypertension, Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

Search for other works by this author on:

Tatsumi Moriya, MD;

4Department of Endocrinology, Diabetes, and Metabolism, Kitasato University School of Medicine, Kanagawa, Japan

Search for other works by this author on:

Sadayoshi Ito, MD;

5Division of Nephrology, Tohoku University Graduate Medical School, Miyagi, Japan

Search for other works by this author on:

Yasuhiko Iwamoto, MD;

6Department of Medicine, Diabetes Center, Tokyo Women's Medical University School of Medicine, Tokyo, Japan

Search for other works by this author on:

Ryuzo Kawamori, MD;

7Department of Medicine, Medical School, Juntendo University, Tokyo, Japan

Search for other works by this author on:

Masahiro Takeuchi, SCD, MPH;

Masahiro Takeuchi, SCD, MPH

8Division of Biostatistics, School of Pharmaceutical Sciences, Kitasato University, Tokyo, Japan

Search for other works by this author on:

Shigehiro Katayama, MD;

9Division of Endocrinology and Diabetes, Department of Medicine, Saitama Medical School, Saitama, Japan

Search for other works by this author on:

Address correspondence and reprint requests to Professor Hirofumi Makino, Department of Medicine and Clinical Science, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama, Japan. E-mail: [email protected]

Diabetes Care 2007;30(6):1577–1578

• Views Icon Views Open Menu
  • Article contents
  • Figures & tables
  • Video
  • Audio
  • Supplementary Material
  • Peer Review

Published ahead of print at http://care.diabetesjournals.org on 26 March 2007. DOI: 10.2337/dc06-1998. Clinical trial reg. no. NCT00153088, clinicaltrials.gov.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Published ahead of print at http://care.diabetesjournals.org on 26 March 2007. DOI: 10.2337/dc06-1998. Clinical trial reg. no. NCT00153088, clinicaltrials.gov.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

You do not currently have access to this content.

Sign in

Pay-Per-View Access

$40.00

3,585 Views

175 Web of Science

Email alerts